【券商聚焦】交银国际指9月港股医药板块表现相对平淡 10月起行业催化剂增多行情有望重启

金吾财讯
Oct 06

金吾财讯 | 交银国际表示,9月以来,内资通过港股通持有医药股的比例持续增加,而外资持仓则从年中开始略有回落,但内外资加大创新药布局的大方向不变。本周,内外资均加仓服务类标的,包括潜在受益于降息的CXO企业,其中内资重点关注昭衍新药晶泰控股及民营医院、流通;外资则重点布局药明康德泰格医药金斯瑞生物。此外,外资亦加仓长期潜力大、当前性价比较高的创新药标的,包括复星医药绿叶制药石药集团。该机构指,本周浙江省公布第一批创新医药技术医保支付激励目录,有望进一步缓解创新药进院难问题。海外,特朗普政府虽宣布对进口创新药加征100%关税,但该机构认为其整体覆盖范围有限、对中国医药产业链影响可控,建议持续关注后续落地及变化情况(见此前报告)。ESMO大会将于今年10月中下旬举行,该机构建议重点关注康方生物科伦博泰荣昌生物等有重磅数据读出的公司。9月港股医药板块表现相对平淡,10月起,随着行业催化剂增多(各项学术大会、利好政策落地),行情有望重启。该机构继续推荐关注以下细分方向:1)创新药:三生制药、德琪医药短期催化剂丰富、估值仍未反映核心大单品价值;先声药业和黄医药传奇生物被明显低估、长期成长逻辑清晰;2)CXO:受益于下游高景气度和融资边际回暖的细分赛道龙头,如药明合联

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10